Clinical and clinicopathological changes in 6 healthy ponies following intramuscular administration of multiple doses of imidocarb dipropionate.
Haematological variables and selected serum indices, particularly those affected by changes in renal and hepatic function, were examined in 6 healthy ponies following 4 intramuscular doses of 4 mg/kg imidocarb dipropionate administered every 72 hours. This treatment regime has been reported to sterilise experimental Babesia equi infections in horses and may have value in preventing the spread of this disease during exportation of possible carrier horses to non-endemic countries. Serum bile acids and serum gamma glutamyltransferase activity were measured to evaluate the effect of this treatment regime on hepatic function. Owing to the absence of any increase in these variables it was concluded that this treatment regime had no clinically detectable deleterious effect on hepatic function in healthy ponies. Urinary gamma glutamyltransferase : creatinine ratios (IU/g), serum creatinine and fractional clearance of sodium, potassium and phosphate (%) were calculated as a measure of renal function. Urinary GGT and urinary GGT : creatinine ratios were significantly elevated on Day 5 of the trial, with 2 of the trial animals also exhibiting mild azotaemia indicative of changes in renal function. The changes in urine GGT : urine creatinine ratios observed in this study also provides evidence of the value of this ratio for the early detection of renal toxicity, following exposure to nephrotoxic agents.
Meyer
C
C
Equis Veterinary Practice, PO Box 2155, Hillcrest 3650, South Africa. bonzi@mweb.co.za
Guthrie
A J
AJ
Stevens
K B
KB
D000818:Animals; D000981:Antiprotozoal Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001404:Babesiosis / Q000517:prevention & control / Q000662:veterinary; D001647:Bile Acids and Salts / Q000378:metabolism; D005260:Female; D006734:Horse Diseases / Q000517:prevention & control; D006736:Horses / Q000097:blood / Q000502:physiology*; D007095:Imidocarb / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology*; D007273:Injections, Intramuscular / Q000662:veterinary; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D007677:Kidney Function Tests / Q000662:veterinary; D008099:Liver / Q000187:drug effects* / Q000378:metabolism / Q000502:physiology; D008111:Liver Function Tests / Q000662:veterinary; D008297:Male; D005723:gamma-Glutamyltransferase / Q000378:metabolism
D000981:Antiprotozoal Agents; D001647:Bile Acids and Salts; D007095:Imidocarb; D005723:gamma-Glutamyltransferase; C031719:imidocarb dipropionate